Transferangebote:

 

Alle Institute dieser Sektion

Treatment of osteoporosis

Prevention and treatment of glucocorticoid-induced osteoporosis

Kurzbeschreibung

Challenge

Glucocorticoids hormones (GCs) are responsible for the modulation of several cellular processes and are involved in metabolism, immune system and foetal development regulation. GCs exert these functions by interacting with the GC receptor (GR) and thereby affecting the expression of key regulatory genes. 
They are used in medicine to treat diseases caused by an overactive immune system, such as allergies, asthma, autoimmune diseases, and inflammation, but also to treat cancer. Nevertheless, long-term GCs administration may cause important side-effects such as hyperglycemia, skin- fragility, muscle weakness, and osteoporosis. For this reason, new GCs analogues with a selective mode of action and preventing GC-dependent side-effects are of substantial therapeutic interest.
 
Technology
The technology relates to a method for therapeutic treatment and prevention of GC-induced osteoporosis (GIO), through keeping c-FOS, c-Jun or AP-1 functions activated or unblocked during GC treatment. It bases on findings that GIO is caused by GC-dependent inhibition of AP-1 function, fostering an imbalance between bone degradation and new bone generation through downstream IL-11 suppression. The invention further provides a method for treating inflammatory diseases, cancer and immune disorders with partial glucocorticoid receptor agonists, without affecting bone regeneration. Furthermore, the technology provides a method to identify novel glucocorticoid derivatives that exhibits anti-inflammatory activity without affecting bone degradation, thus preventing GIO onset.
 
Further Reading
Rauch et al - Cell Metab. 2010 Jun 9;11(6):517-31.

Rauch et al. - FASEB J. 2011, Apr;25(4):1323-32

Technologie

Entwicklungsstand

An PCT application is pending

Vorteile/Nutzen

The invention further provides a method for treating inflammatory diseases, cancer and immune disorders with partial glucocorticoid receptor agonists, without affecting bone regeneration.

Publikationsnummer

WO 2011/154413

Ansprechpartner Patentverwertung

Dr. Sabina Heim

Technology Manager

Ascenion GmbH



T: +49 (0)531 618120-91

F: +49 (0)531 618120-98 

heim@ascenion.de

Angebot ist interessant für

Commercial Opportunity: In-licensing for clinical development and/or collaboration opportunity.

 

Anschrift

  • Beutenbergstraße 11
  • 07745 Jena

Ansprechpartner

 
interner Link: Start Sprungmarke externer Link: http://www.bmwi.de/, öffnet in einem neuen Fenster externer Link: http://www.signo-deutschland.de/hochschulen, öffnet in einem neuen Fenster